Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.24)
# 2,601
Out of 5,182 analysts
54
Total ratings
29.41%
Success rate
4.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Upgrades: Overweight | n/a | $2.35 | - | 7 | Apr 15, 2026 | |
| CRVO CervoMed | Initiates: Overweight | n/a | $3.82 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $8.07 | +123.05% | 1 | Oct 24, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $0.93 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $90.24 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $37.28 | +168.24% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.76 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $8.30 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.21 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $19.16 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.10 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.54 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $87.16 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.31 | +51.06% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.52 | +415.87% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $23.49 | -65.94% | 1 | Mar 20, 2023 |
Alector
Apr 15, 2026
Upgrades: Overweight
Price Target: n/a
Current: $2.35
Upside: -
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.82
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.07
Upside: +123.05%
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.93
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $90.24
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $37.28
Upside: +168.24%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.76
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.30
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.21
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.16
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.10
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.54
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $87.16
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.31
Upside: +51.06%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.52
Upside: +415.87%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $23.49
Upside: -65.94%